Related Experiment Video
Updated: May 29, 2026

Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
Published on: December 17, 2010
Central Diabetes Insipidus Following Steroid Replacement for Hypoadrenalism in Pembrolizumab-Induced Hypophysitis
Abdalrahman Alasmar1, Su Su San2, Thu Ta2
1Internal Medicine, Ungoofaaru Regional Hospital, Ungoofaaru, MDV.
Abstract:
Immune checkpoint inhibitors are increasingly associated with complex immune-related endocrine adverse events that may evolve dynamically over time. We report a rare case of pembrolizumab-induced hypophysitis complicated by central diabetes insipidus, which was unmasked following glucocorticoid replacement. A 68-year-old female patient receiving immunotherapy for lung adenocarcinoma presented with hyponatremia and secondary adrenal insufficiency, followed by abrupt severe hypernatremia after steroid initiation. Subsequent evaluation confirmed central diabetes insipidus, and treatment with desmopressin resulted in clinical and biochemical recovery. This case highlights the diagnostic challenges posed by overlapping pituitary dysfunction and emphasizes the importance of dynamic endocrine reassessment when electrolyte disturbances evolve during immunotherapy.
Related Concept Videos
Diabetes Insipidus I: Introduction
Diabetes Insipidus II: Pathophysiology
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes III: Clinical Manifestations
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cushing Syndrome II: Pathophysiology
